Inhibrx Biosciences Stock Soars on Breakthrough Cancer Trial News
Inhibrx’s ozekibart cut risk of progression or death by 52% in Phase 2 chondrosarcoma trial, doubling median progression-free survival to 5.52 months versus placebo. Shares of INBX jumped about 70% intraday and closed at $28.36 on Oct. 23, then surged another 75–80% after hours. Management plans a BLA filing in Q2 2026. Ozekibart also showed high response rates in colorectal and Ewing sarcoma cohorts.
